BR112019027255A2 - método para reduzir infecção de pulmão - Google Patents

método para reduzir infecção de pulmão Download PDF

Info

Publication number
BR112019027255A2
BR112019027255A2 BR112019027255-0A BR112019027255A BR112019027255A2 BR 112019027255 A2 BR112019027255 A2 BR 112019027255A2 BR 112019027255 A BR112019027255 A BR 112019027255A BR 112019027255 A2 BR112019027255 A2 BR 112019027255A2
Authority
BR
Brazil
Prior art keywords
chelating agent
antibiotic
day
inhaled
dose
Prior art date
Application number
BR112019027255-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Barry Clements
Original Assignee
Respirion Pharmaceuticals Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017902364A external-priority patent/AU2017902364A0/en
Application filed by Respirion Pharmaceuticals Pty Ltd filed Critical Respirion Pharmaceuticals Pty Ltd
Publication of BR112019027255A2 publication Critical patent/BR112019027255A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/133Amines having hydroxy groups, e.g. sphingosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
BR112019027255-0A 2017-06-20 2018-06-20 método para reduzir infecção de pulmão BR112019027255A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2017902364 2017-06-20
AU2017902364A AU2017902364A0 (en) 2017-06-20 Method For Reducing Lung Infection
AU2018900765A AU2018900765A0 (en) 2018-03-08 Method for Reducing Lung Infection
AU2018900765 2018-03-08
PCT/AU2018/050610 WO2018232453A1 (en) 2017-06-20 2018-06-20 Method for reducing lung infection

Publications (1)

Publication Number Publication Date
BR112019027255A2 true BR112019027255A2 (pt) 2020-07-14

Family

ID=64735417

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019027255-0A BR112019027255A2 (pt) 2017-06-20 2018-06-20 método para reduzir infecção de pulmão

Country Status (8)

Country Link
US (1) US11382884B2 (https=)
EP (1) EP3641750A4 (https=)
JP (2) JP7389653B2 (https=)
CN (1) CN111065386A (https=)
AU (3) AU2018286650B2 (https=)
BR (1) BR112019027255A2 (https=)
CA (1) CA3067858A1 (https=)
WO (1) WO2018232453A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210361581A1 (en) * 2018-10-22 2021-11-25 Ioi Oleo Gmbh Additive for a powder material intended for compaction into shaped bodies
CN116173037A (zh) * 2023-04-14 2023-05-30 中国人民解放军总医院 咖啡因在预防和/或治疗急性高原病中的应用
US20250108004A1 (en) * 2023-09-29 2025-04-03 Sterilecare Inc. Aerosol delivery of edta compositions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5497763A (en) 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
WO2008137747A1 (en) 2007-05-02 2008-11-13 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
WO2011142677A1 (en) * 2010-05-11 2011-11-17 Breathe Easy Ltd Methods and compositions for the treatment of lung disorders
AU2016228976B2 (en) * 2015-03-11 2018-11-08 University Of Cincinnati Compositions and methods for treating bacterial infection

Also Published As

Publication number Publication date
EP3641750A1 (en) 2020-04-29
CA3067858A1 (en) 2018-12-27
AU2018286650A1 (en) 2019-12-05
JP2024001036A (ja) 2024-01-09
AU2025256218A1 (en) 2025-11-13
WO2018232453A1 (en) 2018-12-27
CN111065386A (zh) 2020-04-24
EP3641750A4 (en) 2021-03-24
US20200108033A1 (en) 2020-04-09
AU2023285900B2 (en) 2025-11-20
JP2020524172A (ja) 2020-08-13
AU2018286650B2 (en) 2023-09-21
JP7642033B2 (ja) 2025-03-07
AU2023285900A1 (en) 2024-01-18
US11382884B2 (en) 2022-07-12
JP7389653B2 (ja) 2023-11-30

Similar Documents

Publication Publication Date Title
US11116765B2 (en) Liposomal ciprofloxacin formulations with activity against non-tuberculous mycobacteria
US9968555B2 (en) Liposomal formulations that form drug nanocrystals after freeze-thaw
AU2023285900B2 (en) Method For Reducing Lung Infection
Vendrell et al. Evidence of inhaled tobramycin in non-cystic fibrosis bronchiectasis
JP2025098035A (ja) 肺炎症を低減させる方法
EP3551191A1 (en) Aminoglycoside potentiation for treatment of pulmonary bacterial infection
BR122025016291A2 (pt) Uso do agente quelante ácido etilenodiamino tetra-acético (edta) na fabricação de uma formulação inalável, formulação inalável e kit para tratar ou prevenir inflamação no pulmão

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]